[Efficacy and Prognostic Factors of Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia].
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To retrospectively analyze the efficacy and complications of our institution's modified nonmyeloablative allogeneic hematopoietic stem cell transplantation (NST) in treating intermediate-risk acute myeloid leukemia (AML) - first complete remission (CR1) and prognostic factors. METHODS: Clinical data of 50 intermediate-risk AML-CR1 patients who underwent matched related NST at the Fifth Medical Center of Chinese People's Liberation Army General Hospital from August 2004 to April 2021 were collected, the hematopoietic recovery, donor engraftment and complications were observed, and overall survival (OS) rate, leukemia-free survival (LFS) rate, treatment-related mortality (TRM), and cumulative relapse rate were calculated. Statistical analysis of factors affecting prognosis was also preformed. RESULTS: =0.024). CONCLUSION: Modified NST is effective in treating intermediate-risk AML-CR1 patients, however, further expansion of sample size is needed to study prognostic factors.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
Où se fait cette recherche
-
Chinese PLA General Hospital pays non établi dans la noticeÉtablissement de santé
-
Medical College of Chinese PLA pays non établi dans la noticeUniversité ou école supérieure
-
The Fifth Medical Center Department of Hematology pays non établi dans la noticeÉtablissement de santé
Chinese PLA General Hospital, Medical College of Chinese PLA et Department of Hematology — The Fifth Medical Center.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.